<code id='AA865E9630'></code><style id='AA865E9630'></style>
    • <acronym id='AA865E9630'></acronym>
      <center id='AA865E9630'><center id='AA865E9630'><tfoot id='AA865E9630'></tfoot></center><abbr id='AA865E9630'><dir id='AA865E9630'><tfoot id='AA865E9630'></tfoot><noframes id='AA865E9630'>

    • <optgroup id='AA865E9630'><strike id='AA865E9630'><sup id='AA865E9630'></sup></strike><code id='AA865E9630'></code></optgroup>
        1. <b id='AA865E9630'><label id='AA865E9630'><select id='AA865E9630'><dt id='AA865E9630'><span id='AA865E9630'></span></dt></select></label></b><u id='AA865E9630'></u>
          <i id='AA865E9630'><strike id='AA865E9630'><tt id='AA865E9630'><pre id='AA865E9630'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:entertainment    - browse:382
          Adam's take main illustration
          Molly Ferguson/STAT

          Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

          A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

          advertisement

          With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge